Anti-diabetic drugs. Weight reduction as a favourable side effect;Antidiabetika. Gewichtsreduktion als wünschenswerter begleiteffekt

Internist

Volumn 52, Issue 4, 2011, Pages 451-461

  Wirth, A ^a  

^a NONE   (Germany)

Author keywords

Antidiabetic drugs; Antiobesity drugs; Obesity; Reductions in body weight; Type 2 diabetes mellitus

Indexed keywords

ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLITAZONE DERIVATIVE; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; GLUCOSE; INSULIN; METFORMIN; ORAL ANTIDIABETIC AGENT; SULFONYLUREA;

BODY WEIGHT; CARDIOVASCULAR RISK; GLYCEMIC CONTROL; HUMAN; LIFE EXPECTANCY; LIFESTYLE MODIFICATION; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; REVIEW; SIDE EFFECT; WEIGHT REDUCTION;

HUMANS; HYPOGLYCEMIC AGENTS; OFF-LABEL USE; WEIGHT LOSS;

EID: 79953808699     PISSN: 00209554     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00108-011-2811-x     Document Type: Review

References (33)

1. Anderson JW, Kendall CW, Jenkins DJ (2003) Importance of weight management in type 2 diabetes: review with meta-analysis of clinical studies. J Am Coll Nutr 22:331-339 (Pubitemid 37254901)
2. Apovian CM, Bergenstal RM, Cuddihy RM et al (2010) Effects of exenatide combined with lifestyle modification in patients with type 2 diabetes. Am J Med 123:468.e9-17
3. Astrup A, Rössner S, Gaal L van et al (2009) Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet 374:1606-1616
4. Balkau B, Deanfield JE, Després JP et al (2007) International Day for the Evaluation of Abdominal Obesity (IDEA): a study of waist circumference, cardiovascular disease, and diabetes mellitus in 168.000 primary care patients in 63 countries. Circulation 116:1942-1951 (Pubitemid 350287090)
5. Blonde L, Klein EJ, Han J et al (2006) Interim analysis of the effects of exenatide treatment on A1c, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diabetes Obes Metab 8:436-447 (Pubitemid 44349236)
6. Bunck MC, Diamant M, Corner A et al (2009) One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomised, controlled trial. Diabetes Care 32:762-768
7. Buse JB, Rosenstock J, Sesti G et al for the LEAD-6 Study Group (2009) Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 374:39-47
8. Chan JM, Rimm EB, Colditz GA et al (1994) Obesity, fat distribution, and weight gain as risk factors for clinical diabetes in men. Diabetes Care 17:961-969 (Pubitemid 24268605)
9. Chiasson JL, Josse RG, Gomis R et al; STOP-NIDDM Trial Research Group (2002) Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 359:2072-2077
10. Christensen R, Kristensen PK, Bartels EM et al (2007) Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet 370:1706-1713 (Pubitemid 350100788)
11. Colditz GA, Willett WC, Rotnitzky A et al (1995) Weight gain as a risk factor for clinical diabetes in women. Ann Intern Med 122:481-486
12. Dixon JB, O'Brien PE, Playfair J et al (2008) Adjustable gastric banding and conventional therapy for type 2 diabetes: a randomized controlled trial. JAMA 299:316-323 (Pubitemid 351159368)
13. Drucker DJ, Buse JB, Taylor K et al; DURATION-1-Study Group (2008) Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet 372:1240-1250
14. Golay A (2008) Metformin and body weight. Int J Obes (Lond) 32:61-72
15. Hauner H, Petzinna D, Sommerauer B et al (2001) Effect of acarbose on weight maintenance after dietary weight loss in obese patients. Diabetes Obes Metab 3:423-427 (Pubitemid 34030861)
16. Huppertz E, Pieper L, Klotsche J et al (2009) Diabetes mellitus in german primary care: quality of glycaemic control and subpopulations not well controlled - results of the DETECT study. Exp Clin Endocrinol Diabetes 117:6-14
17. James WP, Caterson ID, Coutinho W et al; SCOUT Investigators (2010) Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med 363:905-917
18. Jendle J, Nauck MA, Matthews DR et al (2009) Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. Diabetes Obes Metab 11:1163-1172
19. Johansen K (1999) Efficacy of metformin in the treatment of NIDDM. Diabetes care 22:33-37
20. Kendall DM, Riddle MC, Rosenstock J et al (2005) Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 28:1083-1091 (Pubitemid 40616617)
21. Knowler WC, Barret-Connor E, Fowler SE et al; Diabetes Prevention Program Research Group (2002) Reduction in the incidence of type 2 diabetes with lifestyle intervention and metformin. N Engl J Med 346:393-403
22. Levri KM, Slaymaker E, Last A et al (2005) Metformin as treatment for overweight and obese adults: a systematic review. Ann Fam Med 3:457-461 (Pubitemid 41512664)
23. Linnebjerg H, Park S, Kothare PA et al (2008) Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes. Regul Pept 151:123-129
24. Nauck M, Frid A, Hermansen K et al (2009) Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care 32:84-90
25. Nauck MA, Duran S, Kim D et al (2007) A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. Diabetologia 50:259-267
26. Phung OJ, Scholle JM, Talwar M et al (2010) Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes. JAMA 303:1410-1418
27. Pi-Sunyer X, Blackburn G, Brancati FL; Look AHEAD Research Group (2007) Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the look. Diabetes Care 30:1374-1383 (Pubitemid 46871141)
28. Russell-Jones D, Vaag A, Schmitz O et al (2009) Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial. Diabetologia 52:2046-2055
29. Schultes B, Oltmanns KM, Kern W et al (2003) Modulation of hunger by plasma glucose and metformin. J Clin Endocrinol Metab 88:1133-1141 (Pubitemid 36337767)
30. UKPDS-Study Group (1998) Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352:854-865
31. Verdich C, Flint A, Gutzwiller JP et al (2001) A meta-analysis on the effect of glucagon-like peptide-1 (7-36) amide on ad libitum energy intake in humans. J Clin Endocrinol Metab 86:4382-4389 (Pubitemid 32848563)
32. Willms B, Ruge D (1999) Comparison of acarbose and metformin in patients with type 2 diabetes mellitus insufficiently controlled with diet and sulfonylureas: a randomized, placebo-controlled study. Diabet Med 16:755-761 (Pubitemid 29459274)
33. Wirth A, Engeli S, Hinney A, Reinehr T (2008) Adipositas: Ätiologie, Epidemiologie, Folgekrankheiten, Diagnostik, Therapie, 3. Aufl. Springer, Berlin Heidelberg New York, S 422